PCVX Vaxcyte, Inc. | US92243G1085
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 87.145.780 | 0 | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -7,42 | -8,48 | 12.51% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 7 | 7 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |